A pooled post hoc analysis of phase 3 studies showed rapid and consistent efficiency of Dextenza in the treatment of post-cataract inflammation and pain.
The results, presented at the virtual American Academy of Ophthalmology annual meeting, suggest that “this new option could obviate the need for corticosteroid drops, providing tapered therapy over 30 days,” Francis S. Mah, MD, said.
Corticosteroid drop regimens are the mainstay of cataract surgery to manage pain and inflammation, but they are complex and depend on patient compliance.
“As a component of a regimen that can
Uncategorized